Active Shortage

SANDOZ IRBESARTAN HCT

SANDOZ CANADA INCORPORATED

This is a national manufacturer shortage report. It does not confirm whether the product is unavailable at your local pharmacy — call ahead or ask your pharmacist.

Quick answers

Is there a shortage of SANDOZ IRBESARTAN HCT in Canada?

Yes. SANDOZ IRBESARTAN HCT 25MG 300MG has an active shortage reported to Health Canada (last updated September 14, 2026).

Why is SANDOZ IRBESARTAN HCT not available?

The reason the manufacturer reported: Disruption of the manufacture of the drug.

When will SANDOZ IRBESARTAN HCT be available again?

The manufacturer's estimated resolution date is October 16, 2026. This is an estimate and can change; follow this page to get an email when the status changes.

Can I still get this?Check with your pharmacist

StatusActive Shortage

Same-ingredient products on fileNone found

Expected resolution~18 days remaining (estimate)

Affected strength25MG 300MG

Last updated2026-09-14

What this means

Does this mean my pharmacy is out of stock?

Not necessarily — a national shortage doesn't mean every pharmacy has run out. Some locations may still have stock, especially of a specific strength or pack size.

What should I do?

Contact your pharmacy before your current supply runs low, and ask your pharmacist about next steps if they're out.

Estimated Resolution

2026-10-16

~18 days remaining (estimate)

This is the manufacturer's estimated date, not a guarantee — actual resolution may come earlier or later.

DIN

02337444

Strength

25MG 300MG

Dosage Form

TABLET

Route

ORAL

Active Ingredient

HYDROCHLOROTHIAZIDE IRBESARTAN

Tier

Unrated

Last Updated

2026-09-14

Reason for Shortage

Disruption of the manufacture of the drug.

Source

View original report on healthproductshortages.ca ↗

Past Reports for This Drug

SANDOZ IRBESARTAN HCT has 2 shortage/discontinuation reports on file — this is one of them.

2026-08-24

Resolved

Shortage of an active ingredient.

Other Products from SANDOZ CANADA INCORPORATED

Other Health Canada-approved products made by the same manufacturer — not necessarily related to this shortage, and not necessarily in shortage themselves.

ACETYLCYSTEINE SOLUTION

200MG · DIN 02243098

ACLASTA

5MG · DIN 02269198

ALFENTANIL INJECTION USP

500MCG · DIN 02248181

AMIKACIN SULFATE INJECTION USP

250MG · DIN 02242971

AMIODARONE HYDROCHLORIDE FOR INJECTION

50MG · DIN 02242325

AMOXICILLIN SODIUM AND POTASSIUM CLAVULANATE FOR INJECTION

DIN 02495929